Drug news
FDA Advisory Committee recommends riociguat for PAH and CTEPH
Bayer HealthCare announced that the FDA Cardiovascular and Renal Drugs Advisory Committee recommended approval of the oral soluble guanylate cyclase (sGC) stimulator, riociguat, in two forms of Pulmonary Hypertension. The Committee voted 11 to 0 that riociguat should be approved for the treatment of Pulmonary Arterial Hypertension (PAH) of WHO Group 1. The Committee also voted 11 to 0 that riociguat should be approved for the treatment of Chronic Thromboembolic Pulmonary Hypertension (CTEPH) of WHO Group 4.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins